Additionally, DMF synergistically suppressed HCC progression through the NPM1/ELMO1 signalling pathway, which suggests that simultaneously targeting NPM1 and ELMO1 for HCC metastasis treatment is a promising approach to increase its therapeutic effects. The gene discussed is NPM1; the disease is hepatocellular carcinoma.